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Abstract: The prevalence of HIV-1 associated neurocognitive disorders (HAND) is significantly
greater in older, relative to younger, HIV-1 seropositive individuals; the neural pathogenesis of
HAND in older HIV-1 seropositive individuals, however, remains elusive. To address this knowledge gap, abnormal protein aggregates (i.e., β-amyloid) were investigated in the brains of aging
(>12 months of age) HIV-1 transgenic (Tg) rats. In aging HIV-1 Tg rats, double immunohistochemistry staining revealed abnormal intraneuronal β-amyloid accumulation in the prefrontal cortex
(PFC) and hippocampus, relative to F344/N control rats. Notably, in HIV-1 Tg animals, increased
β-amyloid accumulation occurred in the absence of any genotypic changes in amyloid precursor
protein (APP). Furthermore, no clear amyloid plaque deposition was observed in HIV-1 Tg animals.
Critically, β-amyloid was co-localized with neurons in the cortex and hippocampus, supporting a
potential mechanism underlying synaptic dysfunction in the HIV-1 Tg rat. Consistent with these
neuropathological findings, HIV-1 Tg rats exhibited prominent alterations in the progression of
temporal processing relative to control animals; temporal processing relies, at least in part, on the
integrity of the PFC and hippocampus. In addition, in post-mortem HIV-1 seropositive individuals
with HAND, intraneuronal β-amyloid accumulation was observed in the dorsolateral PFC and hippocampal dentate gyrus. Consistent with observations in the HIV-1 Tg rat, no amyloid plaques were
found in these post-mortem HIV-1 seropositive individuals with HAND. Collectively, intraneuronal
β-amyloid aggregation observed in the PFC and hippocampus of HIV-1 Tg rats supports a potential
factor underlying HIV-1 associated synaptodendritic damage. Further, the HIV-1 Tg rat provides a
biological system to model HAND in older HIV-1 seropositive individuals.
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1. Introduction

iations.

The life expectancy of individuals living with human immunodeficiency virus type 1
(HIV-1) dramatically increased following the advent of combination antiretroviral therapy
(cART; [1,2]). Indeed, HIV-1 seropositive individuals 50 years of age and older account for
approximately 30–50% of all HIV-1 seropositive individuals in high-resource countries [3];
a prevalence which is expected to reach 73% by 2030 [4]. Critically, older HIV-1 seropositive
individuals exhibit a higher frequency of neurocognitive deficits relative to their younger
counterparts [5–7] underscoring the importance of an investigation of the neuropathological
mechanisms underlying these disorders.
Synaptodendritic damage [8,9] and spine dysmorphology/loss [10–12] have been
implicated as key neural mechanisms underlying HAND in HIV-1 seropositive individuals.
Fundamentally, synaptic damage, measured using the presynaptic protein synaptophysin
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and/or the dendritic microtubule activation protein 2, correlates with the severity of neurocognitive impairments [8,13]. Furthermore, multiple biological systems utilized to model
HAND exhibit prominent synaptodendritic damage and/or spine dysmorphology/loss
(e.g., Tat transgenic (Tg) mice: [14,15]; gp120 Tg mice: [16,17]; HIV-1 Tg rat: [18–21]; chimeric
HIV rat: [22]); alterations that generalize across brain regions (e.g., prefrontal cortex (PFC),
nucleus accumbens (NAc), and hippocampus) and ages (e.g., 4 months, 14–17 months, and
20 months of age). However, the factors underlying (e.g., β-amyloid) HIV-1 associated
synaptodendritic damage remain elusive [23,24].
Toxic β-amyloid proteins have deleterious effects on neurons, including synaptodendritic loss and spine dysmorphology (e.g., [25,26]) affording a potential mechanism
underlying synaptodendritic damage in HIV-1. β-amyloid proteins are formed following
the proteolysis of the amyloid precursor protein (APP) along either the nonamyloidogenic or the amyloidogenic pathway (for review, [27]). First, APP is cleaved by either α(non-amyloidogenic) or β- (amyloidogenic) secretase releasing soluble APPα and soluble
APPβ, respectively, from the cell surface. C-terminal fragments of either 83-amino acids
(α-secretase; C83) or 99-amino acids (β-secretase; C99) afford substrates for γ-secretase.
During amyloidogenic processing, the cleavage of C99 by γ-secretase yields either extracellular β-amyloid peptides of varying lengths (e.g., 51-30 amino acid residues) or the APP
intracellular domain. Further cleavage of β-amyloid peptides results in the generation
of the main final forms of β-amyloid, including β-amyloid40 (Aβ40) and β-amyloid42
(Aβ42; [28,29]). Although Aβ40 is the most abundant isoform in the brain [30], Aβ42 is
predominant in neuritic plaques (e.g., [31,32]).
Thus, the present study investigated protein aggregates (i.e., β-amyloid) as a potential neuropathological mechanism underlying synaptic dysfunction in HIV-1. First,
β-amyloid protein aggregates were assessed in the brains of aging (>12 months of age)
HIV-1 transgenic (Tg) and F344/N control rats. The HIV-1 Tg rat expresses seven of the
nine HIV-1 genes (deletion of the pol and gag genes) constitutively throughout development [33] and affords a biological system to model age-related disease progression [20].
Second, the nature of β-amyloid accumulation (i.e., intraneuronal vs. extracellular plaques)
was examined in the post-mortem brains of HIV-1 seropositive individuals with HAND.
Examination of β-amyloid protein accumulation and its co-localization with neurons affords an opportunity to understand the fundamental factors underlying HIV-1 associated
synaptodendritic damage.
2. Materials and Methods
2.1. Experiment 1: HIV-1 Transgenic Rats
All animals were housed and cared for in AAALAC-accredited facilities according to
guidelines established by the National Institutes of Health. The protocols were approved
by the Institutional Animal Care and Use Committee (IACUC) at the University of South
Carolina (Federal Assurance #D16-00028).
2.1.1. Neuroanatomical Assessments
Animals
Aging (>12 months of age) Fischer HIV-1 Tg rats and F344/N control rats were pairhoused in a controlled environment. F344/N control animals were procured from Envigo
Laboratories (Indianapolis, IN, USA), whereas HIV-1 Tg animals were bred by housing a
control female and HIV-1 Tg male together at the University of South Carolina. Animals
were maintained under a 12:12 light/dark cycle with ad libitum access to food (Pro-Lab
Rat, Mouse, Hamster Chow #3000) and water.
Immunofluorescence Staining
Animals (HIV-1 Tg: male, n = 4; female, n = 4; F344/N Control: male, n = 4; female,
n = 4) were deeply anesthetized using sevoflurane (Abbot Laboratories, North Chicago,
IL, USA) and transcardially perfused with 4% paraformaldehyde. After perfusion, brains
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were removed, post-fixed overnight in 4% chilled paraformaldehyde, and sectioned using
a vibratome (100 µm thick coronal slices). Brain sections were incubated with either the
Alexa Fluor® 488 anti-beta Amyloid 1-42 rabbit monoclonal antibody (Cat. No. ab224026,
Abcam, Waltham, MA, USA), Alexa Fluor® 594 anti-NeuN rabbit monoclonal antibody
(Cat. No. ab207279, Abcam, Waltham, MA, USA), or anti-Amyloid Precursor Protein rabbit
monoclonal antibody (Cat. No. ab208744, Abcam, Waltham, MA, USA). Fluorescent images
were acquired using a Nikon D-Eclipse C1 inverted fluorescence microscope. Analyses
were conducted by evaluating the intensity of immunohistochemistry (IHC) staining using
NIS-Elements BR3.10 software (Nikon, Melville, NY, USA), whereby the experimenter was
blind to both genotype and sex.
Neuronal Labeling
Methodological details for ballistic labeling were previously described in detail [34].
Briefly, Tefzel tubing (IDEX Health Sciences, Oak Harbor, WA, USA) was coated with
polyvinylpyrrolidone (PVP). DiOlistic cartridges were prepared using 170 mg tungsten
beads (Bio-Rad, Hercules, CA, USA) and lipophilic dye DiI (Invitrogen, Carlsbad, CA,
USA), which were dissolved in 99.5% pure methylene chloride (Sigma-Aldrich, St. Louis,
MO, USA), and mixed thoroughly. Approximately 100 µL of the bead solution was pipetted
onto a standard glass slide and 150 µL DiI was added on top. The air dried bead/dye
mixture was suspended in deionized H2 O, sonicated to homogenize, added to the PVPcoated Tefzel tubing, and dried under a nitrogen flow (0.4 LPM) for 30 min. Finally, the
Helios gene gun (Bio-Rad, Hercules, CA, USA) was loaded with the previously prepared
PVP-coated Tefzel tubing cartridges. The Dil/tungsten beads within the cartridges were
delivered to the tissue sections using the Helios gene gun system. Helium gas pressure
was set to 100 psi and brain slices were placed approximately 2.5 cm away from the barrel
of the Helios gene gun. DiOlistically labeled tissue sections were mounted onto glass
slides using Pro-Long Gold Antifade reagent (Cat. No. D1306, Fisherscience, MA, USA),
coverslipped, and stored in the dark at 4 ◦ C. Confocal images were obtained within 48 h of
DiOlistic labeling.
2.1.2. Neurocognitive Assessments
Animals
Gap-prepulse inhibition (gap-PPI), tapping the cognitive domain of temporal processing, was evaluated in Fischer F344/N (n = 20 litters) and HIV-1 Tg (n = 17 litters) animals.
Animals were procured in litters (F344/N Control, n = 20 litters; HIV-1 Tg, n = 17 litters)
from Harlan Laboratories, Inc. (Indianapolis, IN, USA), arriving at the animal colony
between postnatal day (PD) 7 and PD 9. HIV-1 Tg and control animals were sampled
from each litter, yielding, HIV-1 Tg: male, n = 37, female, n = 33 and Control: male n = 34;
female, n = 33. Animals (HIV-1 Tg: n = 14; Control: n = 10) exhibiting health issues were
humanely sacrificed prior to the completion of the study. Animals were placed on food
restriction at approximately PD 60, with the goal of maintaining approximately 85% body
weight, during the beginning of a concurrently run operant task. Once animals successfully
acquired the operant task (PD 100-PD 277), rodent food (Pro-Lab Rat, Mouse, Hamster
Chow #3000) was available ad libitum. Water was available ad libitum.
Apparatus
The startle platform (SR-Lab Startle Reflex System, San Diego Instruments, Inc., San
Diego, CA, USA) was enclosed in an isolation cabinet (external dimensions: 10 cm thick,
double-walled, 81 × 81 × 116-cm; Industrial Acoustic Company, Inc., Bronx, NY, USA)
that afforded sound attenuation (30 db(A)) relative to the external environment. Within
the testing chamber, the ambient sound level was 22 db(A). Thirty cm above the Plexiglas
test cylinder was a high-frequency loudspeaker of the SR-Lab system (model#40-1278B,
Radio Shack, Fort Worth, TX, USA), which was utilized for the delivery of all auditory
stimuli. Deflections of the Plexiglas test cylinder were converted into analog signals based
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on a piezoelectric accelerometer attached to the bottom of the cylinder. Following the
digitation (12 bit A to D, recorded at a rate of 2000 samples/sec) of response signals, they
were saved to a hard disk. The SR-LAB Startle Calibration System was utilized to calibrate
response sensitivities.
Procedure
A longitudinal experimental design was utilized to assess the progression of temporal
processing using the gap-prepulse inhibition experimental paradigm. HIV-1 Tg and control
animals were tested for gap-PPI of the auditory startle response beginning at PD 240.
Assessments were conducted every 60 days through PD 540. The methodology for the
assessment of gap-PPI is similar to our prior publication [35]. In brief, the test session,
which was approximately 20 min in duration, began with a 5 min acclimation period in
the dark with 70 db(A) background white noise. Subsequently, six pulse-only ASR trials
were utilized for habituation and separated by a 10 sec intertrial interval (ITI). Thirtysix testing trials were presented in six-trial blocks interdigitated using a Latin Square
experimental design with a variable ITI (15–25 s. A 20 msec gap in background white noise
preceded the auditory startle stimulus (100 db(A) intensity with a 20 msec duration) at
interstimulus intervals (ISIs) of 30, 50, 100, and 200 msec. The gap-PPI assessment included
two control trials, including both the 0 and 4000 msec ISI, providing a reference ASR within
the assessment. Analyses were conducted on the peak ASR amplitude values.
2.2. Experiment 2: Post-Mortem HIV-1 Seropositive Individuals with HAND
Autopsy human brain tissues (n = 9) were provided by the National NeuroAIDS
Tissue Consortium (NNTC). Study participants were HIV-1 seropositive individuals with
symptomatic HAND that had tissue samples from both the dorsolateral prefrontal cortex
(dlPFC; Brodmann’s Area 9 [36]; n = 9) and hippocampus (dentate gyrus; n = 3). Participants
died between 55 and 74 years of age. Additional demographic information is available
in Supplementary Table S1. The NNTC Data Coordinating Center (DCC) approved the
specimen application (Request # R703).
2.2.1. Neuroanatomical Assessments
Immunofluorescence Staining
Human brain tissues were sectioned using a cryostat (50 µm thick coronal slices)
and incubated overnight at 4 ◦ C with either the Alexa Fluor® 488 Anti-beta Amyloid
1-42 antibody (Cat. No. ab224026, Abcam, Waltham, MA, USA), Alexa Fluor® 594 AntiNeuN antibody (Cat. No. ab207279, Abcam, Waltham, MA, USA), or PE Anti-Amyloid
Precursor Protein antibody (Cat. No. ab208744, Abcam, Waltham, MA, USA). Fluorescent
images were acquired using a Nikon D-Eclipse C1 inverted fluorescence microscope. The
fluorescence signal was analyzed using NIS-Elements BR3.10 software.
Thioflavin-S Staining
Brain sections were immersed in a 1% Thioflavin-S (Cat. No. T1892, MilliporeSigma,
Burlington, MA, USA) solution for 2 min at room temperature and differentiated in 70% ethanol
until the sections were clear. Sections were washed with deionized water and mounted with
Pro-Long Gold Antifade reagent.
2.3. Statistical Analysis
Data were analyzed using independent samples t-test (SPSS Statistics 27, IBM Corp.,
Somer, NY, USA), analysis of variance (ANOVA; SPSS Statistics 27), or regression statistical
techniques (GraphPad Prism 5.02, GraphPad Software, Inc., La Jolla, CA, USA). Figures
were created using GraphPad Prism 5. Statistical significance was established at an alpha
level of p ≤ 0.05. Partial eta squared (ηp 2 ) is presented as a measure of effect size.
IHC intensity data for β-amyloid or APP were analyzed using an ANOVA, whereby
genotype (HIV-1 Tg versus Control) and sex (male versus female) served as between-
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subjects factors. The measured intensity of β-amyloid in the hippocampal CA3 region was
transformed using a square root transformation.
The progression of temporal processing was analyzed using regression statistical
techniques. Given the nested experimental design (i.e., rats within litters), individual observations were analyzed using litter means and standard errors, dependent upon biological
sex. Additionally, the mean series imputation method was used for all censored data.
3. Results
3.1. Experiment 1: HIV-1 Transgenic Rats
3.1.1. Neuroanatomical Assessments
IHC (Figure 1) was used to detect the expression of β-amyloid and APP in the medial
prefrontal cortex (mPFC) and hippocampal CA3 region of aging HIV-1 Tg and F344/N
control rats. With regards to β-amyloid, HIV-1 Tg animals exhibited abnormal accumulation
in both the mPFC (main effect of genotype: F(1,15) = 12.6, p ≤ 0.004, ηp 2 = 0.513) and
hippocampal CA3 region (main effect of genotype: F(1,15) = 5.1, p ≤ 0.044, ηp 2 = 0.296)
relative to F344/N control rats (Figure 1D). With regards to APP, no statistically significant
genotype and/or sex differences (p > 0.05) were observed in either the mPFC or CA3 region
of hippocampus (Figure 1E).
Furthermore, two methods (i.e., IHC double staining and DiOlistic labeling) were utilized to evaluate the location of β-amyloid accumulated. First, double staining of β-amyloid
and NeuN, a neuronal marker, supports a strong co-localization of β-amyloid signals and
neurons in both the mPFC and hippocampal region (Figure 1A,B). Second, DiOlistic labeling was also performed using ballistic techniques to confirm the co-localization between
β-amyloid and hippocampal and/or cortical neurons (Figure 2); observations which further
support β-amyloid accumulation as a potential mechanism underlying synaptic alterations
in the HIV-1 Tg rat.
3.1.2. Neurocognitive Assessments
In gap-PPI, the area of the inflection of the ASR response curve (a measure of prepulse
inhibition), was utilized to examine the progression of temporal processing in HIV-1 Tg
and control rats from PD 240 to PD 540 (Figure 3). HIV-1 Tg animals, relative to controls,
displayed a prominent alteration in the progression of temporal processing (Figure 3A).
For control animals, a segmental linear regression provided a well-described fit, with a
linear increase in maximal prepulse inhibition observed through approximately PD 300,
followed by a subsequent decline (R2 = 0.85). In sharp contrast, a first-order polynomial
with a negative slope (i.e., β1 = −392.9 ± 239.6 (X ± 95% confidence interval)) provided
a well-described fit for HIV-1 Tg rats (R2 = 0.83). The magnitude of alterations in the
progression of temporal processing, however, was significantly influenced by the factor of
biological sex (Figure 3B,C).
Complementary analyses of each genotype were conducted to determine the locus
of these interactions. In male rats (Figure 3B), a segmental linear regression provided
a well-described fit for control animals (R2 = 0.76) with maximal inhibition observed at
PD 300, followed by a subsequent decline. Temporal processing in male HIV-1 Tg rats,
however, was well-described by a first-order polynomial with a negative slope R2 = 0.96;
β1 = −392.9 ± 344.12 (X ± 95% confidence interval)). In female rats (Figure 3C), a firstorder polynomial provided an appropriate fit for the development of temporal processing
in control rats (R2 = 0.87). However, female HIV-1 Tg rats failed to exhibit any significant
development in temporal processing from PD 240 to PD 540, evidenced by a horizontal
fit. Aging HIV-1 Tg rats, therefore, displayed prominent alterations in the progression of
temporal processing, with more significant deficits observed in female rats.

Viruses 2022,
2022, 14,
14, x1268
Viruses

14
6 6ofof 15

Figure 1. IHC double
accumulation
of β-amyloid
in the
Figure
double staining
stainingrevealed
revealedan
anabnormal
abnormalintraneuronal
intraneuronal
accumulation
of β-amyloid
in
HIV-1
Tg rat.
(A,B)
Representative
confocal
images
of β-amyloid
expression
and co-localization
with
the
HIV-1
Tg rat.
(A,B)
Representative
confocal
images
of β-amyloid
expression
and co-localization
with
NeuN
(neuronal
marker)
the mPFC
and CA3
of hippocampus
in F344/N
HIV-1
Tg
NeuN
(neuronal
marker)
in theinmPFC
and CA3
area area
of hippocampus
in F344/N
and and
HIV-1
Tg rats.
rats.
The
Alexa
488
green
fluorescence
indicates
expression
of
β-amyloid;
the
Alexa
594
red
fluoThe Alexa 488 green fluorescence indicates expression of β-amyloid; the Alexa 594 red fluorescence
rescence represents NeuN signals. (C) Representative images of amyloid precursor protein (APP)

cally significant (p ≤ 0.05) differences between HIV-1 Tg and control animals are indicated using an
*.

Viruses 2022, 14, 1268

7 of 14

Viruses 2022, 14, x

7 of 15

represents NeuN signals. (C) Representative images of amyloid precursor protein (APP) expression
expression
thehippocampal
mPFC and hippocampal
region
in HIV-1
andAPP
F344/N
rats. APP
expresin the mPFCinand
CA3 region inCA3
HIV-1
Tg and
F344/NTgrats.
expression
is indicated
sion
is
indicated
by
green
fluorescence.
(D)
HIV-1
Tg
rats
exhibited
abnormal
accumulation
of
by green fluorescence. (D) HIV-1 Tg rats exhibited abnormal accumulation of β-amyloid in both the
β-amyloid in both the mPFC and hippocampal CA3 region relative to control animals. (E) StatistimPFC and hippocampal CA3 region relative to control animals. (E) Statistical evaluation of APP in
cal evaluation of APP in the mPFC and hippocampal CA3 areas compared to control rat. Statistithe mPFC and hippocampal CA3 areas compared to control rat. Statistically significant (p ≤ 0.05)
cally significant (p ≤ 0.05) differences between HIV-1 Tg and control animals are indicated using an
differences between HIV-1 Tg and control animals are indicated using an *.
*.

Figure 2. Co-localization of DiOlistically labeled neurons and β-amyloid immunostaining in the
hippocampus, cortex, and prefrontal cortex.

3.1.2. Neurocognitive Assessments
In gap-PPI, the area of the inflection of the ASR response curve (a measure of prepulse inhibition), was utilized to examine the progression of temporal processing in
HIV-1 Tg and control rats from PD 240 to PD 540 (Figure 3). HIV-1 Tg animals, relative to
controls, displayed a prominent alteration in the progression of temporal processing
(Figure 3A). For control animals, a segmental linear regression provided a well-described
fit, with a linear increase in maximal prepulse inhibition observed through approximately PD 300, followed by a subsequent decline (R2 = 0.85). In sharp contrast, a
first-order polynomial with a negative slope (i.e., β1 = −392.9 ± 239.6 (X ± 95% confidence
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3.1.2. Neurocognitive Assessments
In gap-PPI, the area of the inflection of the ASR response curve (a measure of prepulse inhibition), was utilized to examine the progression of temporal processing in
HIV-1 Tg and control rats from PD 240 to PD 540 (Figure 3). HIV-1 Tg animals, relative to
controls, displayed a prominent alteration in the progression of temporal processing
(Figure 3A). For control animals, a segmental linear regression provided a well-described
fit, with a linear increase in maximal prepulse inhibition observed through approximately PD 300, followed by a subsequent decline (R2 = 0.85). In sharp contrast, a
first-order polynomial with a negative slope (i.e., β1 = −392.9 ± 239.6 (X ± 95% confidence
interval)) provided a well-described fit for HIV-1 Tg rats (R2 = 0.83). The magnitude of
Figure 3. Neurocognitive assessments of temporal processing were evaluated using gap-prepulse
alterations in the progression of temporal processing, however, was significantly influinhibition (gap-PPI). The mean peak ASR amplitude response curve for gap-PPI was used to calculate
enced by the factor of biological sex (Figure 3B,C).

prepulse inhibition in HIV-1 Tg and control rats from PD 240 to PD 540. (A) At the genotypic level,
HIV-1 Tg animals exhibited a profound alteration in the progression of temporal processing relative
to control animals. (B,C) Fundamentally, both male (B) and female (C) HIV-1 Tg animals displayed
prominent alterations in the progression of temporal processing; the magnitude of these alterations
was influenced by biological sex.

3.2. Experiment 2: Post-Mortem HIV-1 Seropositive Individuals with HAND
The nature of β-amyloid accumulation (i.e., intraneuronal vs. extracellular plaques)
was examined in the dorsolateral PFC (Area 9, n = 9) and hippocampal dentate gyrus
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(n = 3) of post-mortem HIV-1 seropositive individuals with HAND. Both β-amyloid 1-42
and APP were observed in the dlPFC and hippocampus of HIV-1 seropositive individuals
(Figure 4). Critically, there was no significant β-amyloid plaque deposition in either the
dlPFC or hippocampus, evidenced by the absence of thioflavin-s staining. Meanwhile, the
double staining of β-amyloid with NeuN (a neuronal marker) suggested that β-amyloid
accumulation occurred intraneuronally. Collectively, aged HIV-infected individuals with
HAND exhibited intraneuronal β-amyloid accumulation in the absence of any significant
9 of 15
β-amyloid plaques.
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HIV-1 viral proteins may underlie the abnormal intraneuronal accumulation of
β-amyloid. Specifically, HIV-1 viral proteins may alter β-amyloid synthesis and/or
β-amyloid degradation [23,38–40]; alterations that would decrease the clearance of
β-amyloid. First, the HIV-1 transactivator of transcription (tat) and envelope glycoprotein
gp120 (gp120) may promote the synthesis, secretion, and accumulation of β-amyloid
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HIV-1 viral proteins may underlie the abnormal intraneuronal accumulation of β-amyloid.
Specifically, HIV-1 viral proteins may alter β-amyloid synthesis and/or β-amyloid degradation [23,38–40]; alterations that would decrease the clearance of β-amyloid. First, the
HIV-1 transactivator of transcription (tat) and envelope glycoprotein gp120 (gp120) may
promote the synthesis, secretion, and accumulation of β-amyloid [23,39]. Second, tat
and/or tat-derived peptides may inhibit neprilysin [39,41,42], a key enzyme for β-amyloid
degradation [43]. In addition, it is well-recognized that the blood–brain barrier (BBB) is
compromised by HIV-1 viral proteins (for review, [44]); dysfunction which may influence
β-amyloid homeostasis. For example, HIV-1 particles increased the release of BBB-derived
extracellular vesicles and increased the β-amyloid cargo load in extracellular vesicles [45].
In addition to these neuropathological findings, HIV-1 Tg rats exhibited prominent alterations in the progression of temporal processing relative to control animals. In preclinical
biological systems, temporal processing is often evaluated using prepulse inhibition (PPI)
of the auditory startle response (ASR; [46,47]); the gap-PPI experimental paradigm utilized
in the present study is based on the modification of PPI [48]. Specifically, both PPI and
gap-PPI rely upon the presentation of a discrete prestimulus and a startling stimulus [49].
However, whereas the discrete prestimulus is added (e.g., tone) in PPI, the discrete prestimulus is removed (e.g., a gap in background noise) in gap-PPI. Indeed, in gap-PPI, the
presentation of a discrete prestimulus 30 to 200 msec prior to the startling stimulus elicits
a pronounced reduction in startle response [48]. High translational relevance (e.g., via
utilization of the eyeblink startle experimental paradigm as in [50]) and the well-established
neural circuitry (for review, [51]) illustrate two of the key advantages of utilizing the PPI
and gap-PPI experimental paradigms.
Both the PFC and hippocampus [51], brain regions that exhibit abnormal intraneuronal
β-amyloid accumulation in aging HIV-1 Tg rats, are fundamentally involved in the regulation of PPI. The serial neural circuit mediating PPI begins by relaying auditory input to the
inferior colliculus, which subsequently innervates the superior colliculus. Sensory input
from the superior colliculus is then sent to the pedunculopine tegmental nucleus (PPTg).
Cholinergic projections from the PPTg to the pontine reticular nucleus are relayed to motor
neurons resulting in the elicitation of a startle response. Both the ventral hippocampus [52]
and PFC [53,54] send afferents to the nucleus accumbens (NAc), which subsequently innervates the PPTg. Disruption of neurotransmission in either the ventral hippocampus
(e.g., [55,56]) or PFC (e.g., [57,58]) lead to prominent reductions in PPI; reductions which
resemble those observed in the HIV-1 Tg rat. Given the fundamental role of β-amyloid
in neurotransmission (for review, [59]), it is conceivable that the abnormal intraneuronal
β-amyloid accumulation may underlie the prominent alterations in the progression of
temporal processing observed in HIV-1 Tg animals.
Due to the increasing prevalence of older HIV-1 seropositive individuals, differentiating HAND from other neurodegenerative diseases, including Alzheimer’s disease (AD),
is a fundamental concern; the results of the present paper highlight two facets of HAND
that differentiate it from AD. First, HIV-1 Tg rats and HIV-1 seropositive individuals with
HAND exhibited intraneuronal β-amyloid accumulation in the absence of any significant extracellular β-amyloid plaques. In sharp contrast, one of the salient pathological
features of AD is visible, neuritic extracellular plaques [60,61] comprised primarily of
β-amyloid [62]. It is noteworthy that diffuse (rather than neuritic) β-amyloid plaques were
previously observed in HIV-1 seropositive individuals not receiving cART treatment [63].
In the cART era, when extracellular plaques have been observed in HIV-1 seropositive,
they are primarily located in the perivascular regions [37,38]; again, in sharp contrast to
the location (i.e., initially in the entorhinal cortex and hippocampus; [64]) of extracellular
neuritic plaques associated with AD. Second, temporal processing has been proposed as a
key neurobehavioral mechanism underlying neurocognitive impairments associated with
HIV-1 [65]. Cross-sectional studies have identified deficits in temporal processing and/or
PPI in HIV-1 seropositive individuals with HAND [50] and multiple biological systems
utilized to model HAND (e.g., HIV-1 Tg Rat [66,67]; Stereotaxic Injections of Tat [68,69]
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or gp120 [70]; gp120 Transgenic Mice: [71,72]; Tat Transgenic Mice: [73]). A longitudinal
study in the HIV-1 Tg rat revealed alterations in the progression of temporal processing [35,74]; the present study extends these observations, revealing their generalizability
via the evaluation of temporal processing using a different experimental paradigm. With
regards to AD, however, evidence for alterations in temporal processing has been inconclusive [75]. More broadly, HIV-1 and AD are differentiated by unique neurocognitive
profiles, whereby HAND primarily exhibits a “subcortical” pattern (e.g., attention, executive function; for review [76]). Indeed, evaluating six cognitive measures accurately
discriminates between milder forms of HAND and AD with high accuracy (i.e., 86%; [77]).
There remains, however, a critical need to further delineate similarities and differences in
the phenotype of HAND and AD necessitating a biological system to model HAND in
older HIV-1 seropositive individuals.
Observations across a multitude of studies, including the present one, support the
utility of the HIV-1 Tg rat to model HAND in older HIV-1 seropositive individuals. The
HIV-1 Tg rat, originally reported by Reid et al. [33], expresses seven of the nine HIV-1
genes constitutively throughout development; the deletion of gag and pol renders the
HIV-1 Tg rat non-infectious. The contemporary phenotype of the HIV-1 Tg rat, on the
F344/N background strain, is healthy through advanced age, with approximately 50% of
HIV-1 Tg rats surviving through 21 months of age [78]. Furthermore, HIV-1 Tg rats exhibit
intact sensory (i.e., auditory, visual) and gross-motoric system function through advancing age [74] affording an opportunity to evaluate neurocognitive impairments. Indeed,
cross-sectional studies have demonstrated that neurocognitive impairments observed in
the HIV-1 Tg rat (e.g., attention: [79,80]; executive function: [20,79]; memory: [81–83]; preattentive processes/temporal processing: [66,67]) resemble those commonly altered in HIV-1
seropositive individuals on cART [84,85]. Longitudinal studies have further illustrated
progressive neurocognitive impairments in the HIV-1 Tg rat through the functional lifespan [20,74]. Prominent sex differences in neurocognitive impairments have been observed
in HIV-1 seropositive individuals, whereby female, relative to male, HIV-1 seropositive
individuals exhibit greater neurocognitive impairments [86]; findings which have been
recapitulated in the HIV-1 Tg rat [20,80]. With regards to potential neural mechanisms underlying HAND, the HIV-1 Tg rat exhibits prominent synaptodendritic damage in multiple
brain regions (PFC: [20,21]; Nucleus Accumbens: [18,19,87]); damage which progresses
through six months of age [88]. Additionally, as illustrated in the present study, the intraneuronal nature of β-amyloid accumulation in the HIV-1 Tg rat resembled observations
in HIV-1 seropositive individuals with HAND. Collectively, the neuropathological and
neurocognitive findings of the present study afford additional credence to the utility of the
HIV-1 Tg rat as a biological system to model HAND in older HIV-1 seropositive individuals.
Despite the strengths of the present study, a few limitations must be acknowledged.
First, the absence of matched human control autopsy brain tissue prevents the determination of whether intraneuronal β-amyloid accumulation in HIV-1 seropositive individuals
is abnormal. Given the request for HIV-1 seropositive human autopsy brain tissue from
individuals with neurocognitive impairments, we posit that intraneuronal β-amyloid accumulation, in the absence of prominent β-amyloid plaques, reflects brain pathology in
the current population. Second, neuroanatomical and neurocognitive assessments were
conducted in two separate cohorts of animals; synaptodendritic alterations were not evaluated in the present study. Future studies directly evaluating the relationship between
β-amyloid accumulation, synaptodendritic alterations, and neurocognitive function are
critical to further enhancing our understanding of HAND pathology.
In conclusion, potential abnormal intraneuronal β-amyloid accumulation supports a
potential factor underlying the neural pathogenesis of HAND in the post-cART era. Aging
HIV-1 Tg rats exhibited abnormal intraneuronal β-amyloid accumulation in both the PFC
and hippocampus. Furthermore, the HIV-1 Tg rat exhibited prominent alterations in temporal processing; a cognitive process that is dependent upon intact PFC and hippocampal.
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Elucidating a potential factor underlying synaptodendritic alterations in HIV-1 affords a
key target for future studies evaluating novel therapeutics.
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